OTCPK:AMDH.F

Stock Analysis Report

Executive Summary

CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Risks

  • CardieX is not covered by any analysts.

Share Price & News

How has CardieX's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

AMDH.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

AMDH.F

9.9%

US Medical Equipment

0.6%

US Market

No trading data on AMDH.F.

No trading data on AMDH.F.


Share holder returns

AMDH.FIndustryMarket
7 Day0%1.1%-0.6%
30 Day0%0.6%2.2%
90 Dayn/a2.9%1.1%
1 Yearn/a10.8%9.9%2.9%0.6%
3 Year-77.3%-77.3%70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is CardieX's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is CardieX undervalued based on future cash flows and its price relative to the stock market?

2.62x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for CardieX to establish if it is available at moderate discount.

Unable to calculate intrinsic value for CardieX to establish if it is available at substantial discount.


Price Based on Earnings

CardieX is loss making, we can't compare its value to the US Medical Equipment industry average.

CardieX is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CardieX, we can't assess if its growth is good value.


Price Based on Value of Assets

CardieX is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is CardieX expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CardieX has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine CardieX's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access CardieX's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has CardieX performed over the past 5 years?

-7.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CardieX does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare CardieX's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CardieX's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CardieX has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if CardieX has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CardieX improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CardieX's financial position?


Financial Position Analysis

CardieX is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CardieX's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

CardieX's level of debt (48.2%) compared to net worth is high (greater than 40%).

Unable to establish if CardieX's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

CardieX has sufficient cash runway for 1.9 years based on current free cash flow.

CardieX has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of -26.7% each year.


Next Steps

Dividend

What is CardieX's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CardieX's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CardieX's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CardieX has not reported any payouts.

Unable to verify if CardieX's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CardieX has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CardieX's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Craig Cooper 0

1.8yrs

Tenure

AU$391,595

Compensation

Mr. Craig R. Cooper is the Co-Owner at C2 Ventures Pty Ltd and Chief Executive Officer, Managing Director and Executive Director at AtCor Medical Holdings Limited since December 01, 2017. Mr. Cooper is a M ...


CEO Compensation Analysis

Craig's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Craig to compare compensation growth.


Management Age and Tenure

1.3yrs

Average Tenure

The average tenure for the CardieX management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.2yrs

Average Tenure

The average tenure for the CardieX board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyAU$1,151,59522 May 19
C2 Ventures Pty. Ltd.
EntityCompany
Shares54,616,769
Max PriceAU$0.021

Ownership Breakdown


Management Team

  • Craig Cooper

    CEO, MD & Director

    • Tenure: 1.8yrs
    • Compensation: AU$391.60k
  • Doug Kurschinski

    Executive VP & Head of Global Sales for AtCor Medical Division

    • Tenure: 0yrs
    • Compensation: AU$360.84k
  • Jarrod White

    CFO & Company Secretary

    • Tenure: 1.5yrs
  • ZiHan Lin

    Vice President of Corporate Development

    • Tenure: 1.2yrs
  • Chris Dax

    Vice President of Operations

    • Tenure: 0.3yrs
  • Antony Sloan

    Global Head of Marketing and Communications

    • Tenure: 0yrs

Board Members

  • Niall Charles Cairns (55yo)

    Interim Chairman of the Board

    • Tenure: 0.6yrs
    • Compensation: AU$28.00k
  • Craig Cooper

    CEO, MD & Director

    • Tenure: 1.8yrs
    • Compensation: AU$391.60k
  • Randall Nelson (62yo)

    Independent Non-Executive Director

    • Tenure: 3.8yrs
    • Compensation: AU$27.96k
  • Harry Kim

    Special Advisor

    • Tenure: 0.5yrs

Company Information

CardieX Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CardieX Limited
  • Ticker: AMDH.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$19.474m
  • Listing Market Cap: AU$13.185m
  • Shares outstanding: 695.50m
  • Website: https://cardiex.com

Location

  • CardieX Limited
  • 1059–1063 Victoria Road
  • Suite 11
  • West Ryde
  • New South Wales
  • 2114
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CDXASX (Australian Securities Exchange)YesOrdinary SharesAUAUDNov 2005
AMDH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2005

Biography

CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company offers SphygmoCor system for centra ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 23:58
End of Day Share Price2019/07/11 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.